Benralizumab Demonstrates Favorable Results in Subgroup Analysis of Japanese Bronchial Asthma Patients: AZ

AstraZeneca said on April 21 that a subgroup analysis of Japanese patients in a PIII multinational study for the IL-5 inhibitor benralizumab showed that the efficacy and safety profiles of the agent is consistent with the results from the whole...read more